비뇨기과 의료기기 시장 : 제품 유형별, 기술별, 사용 형태별, 환자 유형별, 소재별, 용도별, 최종 사용자별, 유통 채널별 시장 예측(2026-2032년)

The Urology Devices Market is projected to grow by USD 56.47 billion at a CAGR of 8.20% by 2032.

The urology devices market is being shaped by aging populations, higher diagnosis of urinary stone disease, benign prostatic hyperplasia, urinary incontinence, prostate cancer, bladder cancer, chronic kidney disease, and hospital-acquired urinary tract complications. Verified clinical and public health evidence links these conditions to increasing procedural demand across diagnostic urology, endourology, continence care, dialysis access support, and oncologic urology.

Demand is strongest for minimally invasive urology devices, urological endoscopes, stone management devices, urinary catheters, urodynamic systems, laser systems, stents, guidewires, and robotic-assisted surgical platforms that support shorter hospital stays, faster recovery, improved procedural precision, and lower infection risk when used within validated care pathways.

Transformative Shifts in the Urology Devices Landscape

The competitive landscape is shifting from conventional reusable instruments toward digitally enabled, single-use, and procedure-specific urology solutions. Single-use ureteroscopes and cystoscopes are gaining traction where infection control, reprocessing capacity, cross-contamination risk, and predictable device performance are procurement priorities.

At the same time, thulium fiber lasers, high-power holmium lasers, advanced imaging, suction-assisted stone removal, antimicrobial and hydrophilic catheter materials, urodynamic workflow automation, and ambulatory surgery center adoption are changing how urologic care is delivered across hospitals and outpatient settings. These shifts are supported by clinical preferences for minimally invasive treatment, shorter recovery times, and evidence-based device selection.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across diagnosis, treatment planning, operating room workflow, and post-procedure monitoring in urology. AI-assisted imaging can support lesion recognition, stone characterization, prostate assessment, kidney imaging interpretation, and workflow standardization when validated against clinical evidence and used under physician oversight.

The strongest near-term value is expected in decision support, predictive maintenance, inventory optimization, procedure documentation, surgical video analytics, and patient risk stratification. Adoption will depend on FDA and EU MDR compliance, cybersecurity, interoperability with hospital systems, algorithm explainability, bias management, and clinician trust in real-world performance.

Key Regional Insights

North America remains a leading region due to advanced hospital infrastructure, high procedural volumes, established reimbursement pathways, strong specialty access, and rapid adoption of robotic urology surgery, lasers, single-use scopes, urodynamic diagnostics, and outpatient urology procedures. Europe is influenced by EU MDR scrutiny, clinical evidence requirements, value-based purchasing, and strong demand across Germany, France, Italy, Spain, and the United Kingdom for endoscopy, stone treatment, continence care, and cancer-related urology devices.

Asia-Pacific is expanding through healthcare investment in China, India, Japan, South Korea, Australia, and ASEAN markets, supported by aging populations, rising diagnosis of kidney stones, BPH, prostate cancer, and chronic kidney disease, and broader access to tertiary care. Latin America is led by Brazil and Mexico, where private hospital investment supports adoption of minimally invasive devices despite uneven public-private access. The Middle East, especially GCC markets, is investing in specialty hospitals, digital health, and advanced surgical platforms, while Africa shows long-term need for affordable urinary catheters, endoscopes, stone treatment tools, and essential urologic care infrastructure.

Key Group Insights

The European Union emphasizes regulatory compliance, clinical evidence, post-market surveillance, traceability, and sustainable procurement, making CE-marked innovation and EU MDR readiness critical for urology device suppliers. G7 markets favor premium urology devices with documented safety, procedural efficiency, and outcome benefits, while NATO-aligned procurement environments increasingly prioritize supply security, cybersecurity, continuity of medical technology sourcing, and resilience against logistics disruption.

BRICS countries are central to volume-based demand because China, India, Brazil, Russia, and South Africa combine large patient pools with expanding hospital capacity and rising diagnosis of urologic conditions. ASEAN markets are scaling access through urban specialty centers, regional hospital upgrades, and greater availability of endourology services, while GCC countries are accelerating adoption of advanced urology platforms through public healthcare modernization, medical tourism initiatives, and specialty surgical investment.

Key Country Insights

The United States leads in innovation, FDA-cleared devices, robotic-assisted surgery, laser lithotripsy, and outpatient urology adoption, while Canada emphasizes evidence-based procurement, safety, and equitable access across public health systems. Mexico and Brazil support Latin American momentum through private hospital investment, urology specialty expansion, and rising diagnosis of kidney stones, BPH, urinary incontinence, and urologic cancers.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central for urological endoscopy, laser systems, urinary catheters, BPH therapy, urodynamics, and cancer-related urology care, while Russia maintains demand for essential and advanced devices despite procurement complexity and supply constraints. China and India provide large-scale procedural demand supported by hospital infrastructure development and growing specialist capacity; Japan and South Korea favor advanced technology, precision instruments, and high-quality surgical care; and Australia combines guideline-driven practice, specialty access, and adoption of minimally invasive urology devices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated portfolios across single-use endoscopy, stone management, catheter safety, laser systems, urodynamic diagnostics, BPH therapy, and digitally connected urology platforms. Commercial success depends on proving clinical outcomes, reducing total procedure cost, supporting infection prevention, and aligning product design with hospital workflow and outpatient care models.

Manufacturers should localize pricing, training, service, and regulatory strategies by region; build AI governance early; strengthen supply resilience; and expand physician education through simulation, remote proctoring, digital training modules, and data-backed evidence packages for hospitals and ambulatory surgery centers. Partnerships with clinicians, payers, and procurement teams can improve adoption where devices demonstrate safety, efficiency, and measurable patient benefit.

Research Methodology

This executive summary is based on a structured research methodology combining secondary research, regulatory review, clinical guideline assessment, product approval tracking, reimbursement signals, trade data, peer-reviewed evidence, public health indicators, and healthcare infrastructure analysis.

Insights are triangulated through demand-side and supply-side analysis, including device adoption patterns, procedure migration, hospital procurement behavior, regional access dynamics, regulatory pathways, and competitive positioning across urology endoscopy, stone treatment, catheters, urodynamics, BPH therapy, urinary incontinence care, oncologic urology, and surgical technologies.

Conclusion

The urology devices market is entering a phase defined by minimally invasive care, digital integration, infection prevention, and broader access to specialty treatment. Devices that improve procedural efficiency, patient safety, clinical workflow, and measurable outcomes will remain best positioned across hospitals, specialty clinics, and ambulatory surgery centers.

Long-term industry momentum will be driven by aging demographics, rising urologic disease burden, outpatient procedure migration, AI-enabled workflows, regulatory quality expectations, and regional healthcare investment. Companies that combine innovation with evidence, affordability, regulatory readiness, supply resilience, and physician training will be better positioned to build durable competitive advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Urology Devices Market, by Product Type

• 7.1. Endoscopes
  • 7.1.1. Cystoscopes
    • 7.1.1.1. Flexible
    • 7.1.1.2. Rigid
  • 7.1.2. Ureteroscopes
  • 7.1.3. Nephroscopes
• 7.2. Dialysis Devices
  • 7.2.1. Hemodialysis Devices
  • 7.2.2. Peritoneal Dialysis Devices
• 7.3. Lithotripsy Devices
• 7.4. Urodynamic Systems
• 7.5. Catheters
  • 7.5.1. Intermittent Catheters
  • 7.5.2. Indwelling Catheters
  • 7.5.3. External Catheters
• 7.6. Urinary Stents
  • 7.6.1. Ureteral Stents
    • 7.6.1.1. Double J Stents
    • 7.6.1.2. Multi-Length Stents
  • 7.6.2. Prostatic Stents
• 7.7. Urinary Incontinence Devices
  • 7.7.1. Artificial Urinary Sphincters
  • 7.7.2. Slings
  • 7.7.3. Vaginal Pessaries
• 7.8. Guidewires
  • 7.8.1. Hydrophilic Guidewires
  • 7.8.2. PTFE Coated Guidewires
  • 7.8.3. Hybrid Guidewires
• 7.9. Biopsy Devices
  • 7.9.1. Prostate Biopsy Needles
  • 7.9.2. Biopsy Guidance Systems

8. Urology Devices Market, by Technology

• 8.1. Laser-Based Technology
  • 8.1.1. Holmium Laser
  • 8.1.2. Thulium Laser
  • 8.1.3. Diode Laser
• 8.2. Ultrasound-Based Technology
• 8.3. Radiofrequency-Based Technology
• 8.4. Robotic-Assisted Technology
• 8.5. Imaging-Guided Technology

9. Urology Devices Market, by Usage Type

• 9.1. Disposable
• 9.2. Reusable

10. Urology Devices Market, by Patient Type

• 10.1. Adult
• 10.2. Pediatric

11. Urology Devices Market, by Material

• 11.1. Silicone-Based
• 11.2. Latex-Based
• 11.3. Polyurethane-Based
• 11.4. PTFE-Based

12. Urology Devices Market, by Application

• 12.1. Urolithiasis
  • 12.1.1. Kidney Stones
  • 12.1.2. Ureteral Stones
  • 12.1.3. Bladder Stones
• 12.2. Urinary Incontinence
• 12.3. Benign Prostatic Hyperplasia
• 12.4. Prostate Cancer
• 12.5. Bladder Cancer
• 12.6. Chronic Kidney Disease
• 12.7. End-Stage Renal Disease

13. Urology Devices Market, by End User

• 13.1. Ambulatory Surgical Centers
• 13.2. Hospitals
  • 13.2.1. Public
  • 13.2.2. Private
• 13.3. Urology Clinics
• 13.4. Specialty Clinics
  • 13.4.1. Urology Clinics
  • 13.4.2. Dialysis Centers
• 13.5. Home Care Settings

14. Urology Devices Market, by Distribution Channel

• 14.1. Offline
• 14.2. Online

15. Urology Devices Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Urology Devices Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Urology Devices Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. Argon Medical Devices Inc.
• 19.3. Asahi Kasei Corporation
• 19.4. B. Braun Melsungen AG
• 19.5. Baxter International Inc.
• 19.6. Becton Dickinson and Company
• 19.7. Boston Scientific Corporation
• 19.8. Cardinal Health Inc.
• 19.9. Coloplast A/S
• 19.10. ConvaTec Group plc
• 19.11. Cook Medical LLC
• 19.12. Dornier MedTech GmbH
• 19.13. Endo International plc
• 19.14. Fresenius Medical Care AG & Co. KGaA
• 19.15. Hollister Incorporated
• 19.16. Intuitive Surgical Inc.
• 19.17. Johnson & Johnson Services, Inc
• 19.18. KARL STORZ SE & Co. KG
• 19.19. Laborie Medical Technologies Corp.
• 19.20. Medtronic plc
• 19.21. Nipro Corporation
• 19.22. Olympus Corporation
• 19.23. Promedon S.A.
• 19.24. Richard Wolf GmbH
• 19.25. Siemens Healthineers AG
• 19.26. Stryker Corporation
• 19.27. Teleflex Incorporated
• 19.28. Terumo Corporation